First clinical evaluation report of using the Topol device to deliver PIPAC treatment

[1]  M. Pocard,et al.  PIPAC nebulizer: How to test the new devices in the market, expert recommendations. , 2022, Journal of visceral surgery.

[2]  M. Pocard,et al.  Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study , 2022, Annals of Surgical Oncology.

[3]  M. Pocard,et al.  Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC) , 2022, Pleura and peritoneum.

[4]  F. Lordick,et al.  Primary and metastatic peritoneal surface malignancies , 2021, Nature Reviews Disease Primers.

[5]  M. Hübner,et al.  Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. , 2019, The Lancet. Oncology.

[6]  M. Pocard,et al.  PIPAC: 8 key points for a good practice with video. , 2019, Journal of visceral surgery.

[7]  F. Bérard,et al.  Severe hypersensitivity reactions to platinum compounds post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report , 2018, Cancer Chemotherapy and Pharmacology.

[8]  M. Pocard,et al.  Pleura and Peritoneum , 2018 .

[9]  M. Mortensen,et al.  Environmental safety during the administration of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) , 2016, Pleura and peritoneum.

[10]  C. Tempfer,et al.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy , 2016, World Journal of Surgical Oncology.

[11]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.